MX2018013959A - Metodos para tratar enfermedad autoinmune usando celulas t alogenicas. - Google Patents

Metodos para tratar enfermedad autoinmune usando celulas t alogenicas.

Info

Publication number
MX2018013959A
MX2018013959A MX2018013959A MX2018013959A MX2018013959A MX 2018013959 A MX2018013959 A MX 2018013959A MX 2018013959 A MX2018013959 A MX 2018013959A MX 2018013959 A MX2018013959 A MX 2018013959A MX 2018013959 A MX2018013959 A MX 2018013959A
Authority
MX
Mexico
Prior art keywords
methods
allogeneic
treating autoimmune
cells
autoimmune disease
Prior art date
Application number
MX2018013959A
Other languages
English (en)
Inventor
Khanna Rajiv
Original Assignee
Council Queensland Inst Medical Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Council Queensland Inst Medical Res filed Critical Council Queensland Inst Medical Res
Publication of MX2018013959A publication Critical patent/MX2018013959A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se proporcionan en la presente composiciones que comprenden celulas T citotóxicas alogenicas que expresan un receptor de celulas T que se une especificamente a un peptido de virus de Epstein-Barr (EBV) presentado en un MHC clase I y metodos de tratamiento de enfermedades autoinmunes con esta composicion.
MX2018013959A 2016-05-25 2017-05-25 Metodos para tratar enfermedad autoinmune usando celulas t alogenicas. MX2018013959A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662341360P 2016-05-25 2016-05-25
US201662359326P 2016-07-07 2016-07-07
US201762487814P 2017-04-20 2017-04-20
PCT/IB2017/000805 WO2017203368A1 (en) 2016-05-25 2017-05-25 Methods of treating autoimmune disease using allogeneic t cells

Publications (1)

Publication Number Publication Date
MX2018013959A true MX2018013959A (es) 2019-08-22

Family

ID=60411139

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018013959A MX2018013959A (es) 2016-05-25 2017-05-25 Metodos para tratar enfermedad autoinmune usando celulas t alogenicas.

Country Status (14)

Country Link
US (2) US20210220402A1 (es)
EP (1) EP3463399A4 (es)
JP (2) JP7136701B2 (es)
KR (2) KR20230113817A (es)
CN (1) CN109475578A (es)
AU (1) AU2017271134A1 (es)
BR (1) BR112018073136A2 (es)
CA (1) CA3024277A1 (es)
CL (1) CL2018003284A1 (es)
IL (1) IL262989A (es)
MX (1) MX2018013959A (es)
PH (1) PH12018502402A1 (es)
SG (1) SG11201809534UA (es)
WO (1) WO2017203368A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
DK2812431T3 (da) 2012-02-09 2019-10-14 Baylor College Medicine Peptidblandinger til generering af multivirale ctl'er med bred specificitet
CN113943703A (zh) 2015-09-18 2022-01-18 贝勒医学院 来自病原体的免疫原性抗原鉴定以及与临床效力的相关性
MX2018013963A (es) 2016-05-25 2019-08-22 Council Queensland Inst Medical Res Metodos de inmunoterapia.
WO2018136762A1 (en) * 2017-01-20 2018-07-26 Atara Biotherapeutics, Inc. Methods of treating multiple sclerosis using autologous t cells
WO2019136379A1 (en) * 2018-01-08 2019-07-11 Atara Biotherapeutics, Inc. Systems and methods for distributing cell therapies
JP2021526826A (ja) * 2018-06-13 2021-10-11 ザ カウンシル オブ ザ クイーンズランド インスティテュート オブ メディカル リサーチ ウイルス検出アッセイ
JP2022519378A (ja) * 2019-02-08 2022-03-23 グッド ティー セルズ、 インコーポレイテッド がん治療のためのｔ細胞の活性化方法
JP2022542968A (ja) * 2019-07-29 2022-10-07 ベイラー カレッジ オブ メディスン 抗原特異的ｔ細胞バンク及びそれを製造する方法並びにそれを治療に使用する方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO784197A0 (en) * 1997-07-10 1997-08-07 Csl Limited Treatment of nasopharyngeal carcinoma
US20030147865A1 (en) * 2002-02-07 2003-08-07 Benoit Salomon Cell therapy using immunoregulatory T-cells
US20090324630A1 (en) * 2008-04-21 2009-12-31 Jensen Michael C Fusion multiviral chimeric antigen
EP4285922A1 (en) * 2011-05-26 2023-12-06 Geneius Biotechnology Investments, LLC Modulated immunodominance therapy
KR101749195B1 (ko) * 2011-12-12 2017-06-20 셀 메디카 리미티드 T 세포들을 증식시키는 방법
CN104491857B (zh) * 2014-12-24 2018-08-31 深圳市中美康士生物科技有限公司 一种用于免疫治疗ebv相关疾病的抗原组合物、生物制剂及其制备方法

Also Published As

Publication number Publication date
US20210220402A1 (en) 2021-07-22
EP3463399A1 (en) 2019-04-10
JP7136701B2 (ja) 2022-09-13
RU2018145500A3 (es) 2020-10-15
EP3463399A4 (en) 2020-03-18
SG11201809534UA (en) 2018-12-28
RU2018145500A (ru) 2020-06-25
IL262989A (en) 2018-12-31
CL2018003284A1 (es) 2019-06-14
WO2017203368A1 (en) 2017-11-30
PH12018502402A1 (en) 2019-04-08
US20220409662A1 (en) 2022-12-29
CA3024277A1 (en) 2017-11-30
JP2019516751A (ja) 2019-06-20
CN109475578A (zh) 2019-03-15
JP2022174151A (ja) 2022-11-22
JP7454617B2 (ja) 2024-03-22
KR20230113817A (ko) 2023-08-01
BR112018073136A2 (pt) 2019-03-12
KR20190030661A (ko) 2019-03-22
AU2017271134A1 (en) 2019-01-03

Similar Documents

Publication Publication Date Title
PH12018502402A1 (en) Methods of treating autoimmune disease using allogeneic t cells
GB2564823A8 (en) Compositions and methods for T-cell receptors reprogramming using fusion proteins
MX2017014822A (es) Composiciones y métodos para la reprogramación del tcr con proteínas de fusión.
MX2019011514A (es) Receptores quimericos nkg2d truncados y usos de los mismos en inmunoterapia con celulas asesinas naturales.
MX2019003886A (es) Receptores de antigenos quimericos para el tratamiento del cancer.
CO2017000507A2 (es) Receptor quimérico de antígeno bcma
CO2017000506A2 (es) Receptor quimérico de antígeno cll-1
MX2019000180A (es) Composiciones de células t para la inmunoterapia.
MX2023004169A (es) Alteracion de la expresion genetica en celulas t modificadas con el receptor de antigeno quimerico (cart) y usos de las mismas.
PH12017500803A1 (en) Anti-pd-1 antibodies
CL2016003096A1 (es) Métodos para cosechar cultivos de células de mamífero
MX2019014009A (es) Metodos mejorados para la elaboracion de terapias celulares adoptivas.
MX2019014008A (es) Composiciones y usos para inmunoterapia.
MX2016008076A (es) Receptores quimericos de antigeno de mesotelina humana y uso de los mismos.
PH12015500747A1 (en) Compositions and methods for immunotherapy
MX2021001009A (es) Composiciones y métodos para la reprogramación de tcr mediante el uso de proteínas de fusión específicas de la diana.
MX2019012360A (es) Composiciones y metodos mejorados de celulas t.
MX2019000641A (es) Composiciones de mucina1-receptor de antigeno quimerico y metodos para su uso.
MX2018004121A (es) Receptores de antigeno y usos de los mismos.
EP4295914A3 (en) Genetically-engineered drug resistant t cells and methods of using the same
PH12019502036A1 (en) Peptides and methods for the treatment of diabetes
MX2021002225A (es) Composiciones y metodos para la reprogramacion de tcr mediante el uso de proteinas de fusion.
NZ755116A (en) Methods of treating multiple sclerosis using autologous t cells
MX2019010941A (es) Receptores de antigeno y usos de los mismos.
EA201990543A1 (ru) Композиции и способы репрограммирования т-клеточных рецепторов с помощью гибридных белков